Device-Driven DRG Upcoding: When the Implant Changes the Group

Medical device DRG upcoding uses a false description of an implant, procedure or patient’s condition to move a hospital stay into a higher-paying diagnosis-related group. Some Medicare groups make a particular device an alternative to a major complication. That puts the product itself at the center of the payment question. If you work in implant sales, the operating room or hospital coding, you may know where the device actually used and the description behind the bill parted company.

The chain runs from the manufacturer’s representation, through the surgeon’s selection and documentation, to the hospital’s claim. We follow it in that order. The person who knows the implant and the person who knows the billing code may each hold a different part of the explanation.

How Does Reimbursement Work for Medical Devices?

Medicare generally includes an implanted device’s cost in payment for the procedure or hospital stay. For inpatient care, that cost sits inside the diagnosis-related group’s relative weight. The hospital buys an implant, but Medicare ordinarily pays for the stay through a group that includes it.

That arrangement makes the grouping decision commercially important. The manufacturer has a product to sell. The hospital has a purchase cost and an expected payment for the procedure. A representation that the implant qualifies the stay for a higher-paying group can therefore reach both the clinical decision and the hospital’s financial decision.

The hospital is the institutional buyer: it approves products and handles purchasing arrangements. The surgeon may strongly influence which product goes into the patient. In its special fraud alert on physician-owned entities, the HHS Office of Inspector General describes that influence as extending to both the brand and the type of device. The purchaser and the chooser can be different people.

Technical support puts a manufacturer’s representative close to that choice. The Association of periOperative Registered Nurses describes representatives providing instruction when their company’s equipment or implant is used. Its position also recognizes their potential influence on product selection. A representation about an implant can travel through a conversation in the operating room as well as through a reimbursement document.

A procedure code describes the operation. The DRG is the payment group reached from the coded information about the stay. Diagnoses, procedures and patient circumstances feed the grouping decision. The implant’s product description has to connect to the clinical record and the code before it can explain why the hospital claimed a particular group.

For device-driven DRG upcoding, the question is why the inpatient stay reached the more expensive group. The difference can sit inside the bundle, in the description that determined the payment. When a false description drives that payment up, taxpayers pay for the difference.

The FY2026 Spinal-Fusion Example

Under the FY2026 Medicare inpatient rules, MS-DRG 450 covers single-level spinal fusion except cervical with a major complication or comorbidity, or with a custom-made anatomically designed interbody fusion device. MS-DRG 451 is the lower group in the comparison. The device language creates an alternative route into the higher group.

The word doing the work is or.

A review focused entirely on whether the patient had a major complication can miss the device route. For that route, the product’s identity and qualifying characteristics become central.

The published FY2026 relative weights in this comparison are 5.3296 for the higher group and 3.2304 for the lower one.

If the manufacturer described a product as qualifying for the device route, the operative account and product records are where we test that description. The hospital’s coded record then shows whether it used the device route, the complication route or another basis for the group.

The same title structure appears elsewhere in the FY2026 rules. MS-DRGs 426 and 447 also name the custom-made anatomically designed interbody fusion device as an alternative to a major complication. MS-DRG 518 names a disc device or neurostimulator in its back-and-neck procedure title, while MS-DRG 276 names a carotid sinus neurostimulator in its cardiac-defibrillator title.

We give the product description the same scrutiny as a diagnosis that raises the bill. What fact supplied the higher-paying description, and who knew whether it was true?

Why the Grouper Year Changes the Answer

The fiscal year determines which DRG titles, numbers and weights apply. The Centers for Medicare & Medicaid Services changes those features over time, so the device and procedure have to be compared with the rules for the stay being examined.

The device-driven payment policy began with FY2008. Later changes included new groups, deleted groups and revised titles. A familiar number can survive while its wording changes. An older group can disappear altogether.

The cardiac-defibrillator family illustrates the problem. CMS deleted MS-DRGs 222 through 227 effective October 1, 2023, and replaced them with 275, 276 and 277. The following fiscal year’s rule retitled the middle group.

The spinal-fusion groups also changed. Earlier families were reorganized around single-level and multiple-level procedures. By FY2026, the coronary-stent grouping distinguished procedures with an intraluminal device from those without one, replacing the older distinction between drug-eluting and bare-metal stents.

We compare the manufacturer’s dated coding guidance with the procedure, the hospital’s documentation and the grouper version used.

The Implant Record Connects the Product to the Claim

The implant record supplies a connection that Medicare claims have lacked: the identity of the particular device. The Food and Drug Administration’s device-identification rule requires a unique device identifier on device labels, subject to exceptions. In August 2019, the Centers for Medicare & Medicaid Services told the HHS Office of Inspector General that the recommendation to put device identifiers on claims remained unimplemented.

That gap matters when the payment turns on a particular implant. A claim can supply the coded description used for payment while the hospital’s product records supply the device behind it. We connect the label and implant documentation to the operative report, the procedure code and the group claimed for the stay.

In documented consignment arrangements, a manufacturer retains ownership of inventory at the hospital until the product is used or implanted. Its use then becomes both a clinical event and the event that completes the sale.

Orthofix describes spinal implant sets that include components in different sizes so the physician can select the appropriate implant for the patient. Some sets travel to the hospital for a single procedure while others remain with high-volume users. The company says a typical surgery uses only some of the implants in a set. That commercial detail gives us a more precise question than what arrived at the hospital: which component from the available set went into this patient?

The nursing record can also locate the manufacturer’s involvement. The nursing association’s position calls for documenting the representative’s identity, company and time in the room under the hospital’s policy. Where that information was recorded, it connects a company representative to a particular operation.

A product selected for surgery, a product charged to the hospital and a product described for Medicare payment should tell a coherent story. When they tell different stories, we work with the people who understand how the descriptions were chosen.

When Manufacturer Guidance Becomes the Claim

A manufacturer can cause a provider’s false claim through the coding or admission advice it supplies. The government has pursued that chain in cases involving both the procedure billed and the setting in which it was billed.

EndoGastric Solutions and the More Invasive Procedure Code

EndoGastric Solutions agreed in February 2014 to pay up to $5.25 million to resolve allegations involving misleading reimbursement advice and kickbacks. Its EsophyX device treated gastroesophageal reflux disease through a less invasive alternative to a procedure requiring abdominal incisions.

The Justice Department alleged that EndoGastric caused providers to use codes for the more invasive procedure. Those codes paid more. According to the government’s account, federal health care programs consequently overpaid for the EsophyX procedures.

A former employee brought the whistleblower case that the settlement resolved. The device made the procedure less invasive. The company’s advice allegedly made the bill describe more invasive surgery.

Kyphoplasty and the Inpatient Admission

Medtronic Spine, the corporate successor to Kyphon, paid $75 million in 2008 to settle allegations about counseling hospitals to perform kyphoplasty as an inpatient procedure. Kyphoplasty is a minimally invasive treatment for certain spinal fractures. The government contended that many of the procedures should have been performed on an outpatient basis.

In its later account of the hospital settlements, the Justice Department described the manufacturer’s alleged role as causing hospitals to submit false claims through that counseling. Former reimbursement and regional sales managers were the whistleblowers behind the hospital case.

The manufacturer’s advice allegedly changed the setting billed to Medicare. The case puts reimbursement personnel directly inside the chain between the product’s use and the hospital’s payment request.

A Closed-Chest Procedure Described as Open Surgery

A whistleblower’s complaint against Endoscopic Technologies alleged a particularly direct coding mismatch. The complaint said the company’s stand-alone surgical ablation system used a minimally invasive closed-chest approach, while the company instructed hospitals to use an open-approach procedure code:

The whistleblower alleged that this advice increased reimbursement. The comparison sits in the procedure itself: the approach described for the product and the approach described by the recommended code. Those are facts an operating-room specialist and a coder can examine together.

What Kind of Proof Is Needed to Be a Whistleblower?

For medical device DRG upcoding, useful proof connects what was implanted and performed to what the hospital claimed, why that description increased payment and who knew about the difference. Your account may begin with the manufacturer’s instruction, the operation or the coding decision. We work with you to connect it to the rest of the transaction.

A 2020 review in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, describes claims for more expensive categories of care than were actually provided as a recurring False Claims Act pattern. It centers the analysis on the payment request and the information about goods or services that request contains. For this page’s reader, the practical comparison is the implant and operation against their description in the bill.

The clinical record matters independently of the billing pattern. In its August 1998 report, Using Software to Detect Upcoding of Hospital Bills, the HHS Office of Inspector General tested software predictions against blinded medical-record reviews. Reviewers derived diagnosis and procedure codes from the records and generated a new DRG. When a review found a discrepancy, the reviewer first compared the hospital’s reasoning with their own. Disagreements that remained went to another blind review.

We want to hear what you saw in the ordinary course of your work and how the decision reached the claim. That is where industry experience gives the paperwork meaning.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know What Went Into the Patient

If you saw implant documentation or coding instructions turn into a higher hospital bill, speak to one of our Whistleblower Experts about the device and the decision behind that claim. We work beside you to build your strongest device fraud whistleblower case from the clinical and commercial details you understand. We bring in medical device fraud whistleblower lawyers who know DRG coding cases and stay with you through the process.